Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kentaro Sakamaki

Showing results (1-10 of 151) with videos related to

Pageof 16
Sort By:
Nihon Geka Gakkai Zasshi|April 16, 2016
[PRIMER FOR SURGICAL CLINICAL TRIALS]Kentaro Sakamaki, Takeharu Yamanaka
BMC Medical Research Methodology|October 3, 2022
Statistical methods and graphical displays of quality of life with survival outcomes in oncology clinical trials for supporting the estimand frameworkKentaro Sakamaki, Takuya Kawahara
Trials|November 9, 2021
Definitions and elements of endpoints in phase III randomized trials for the treatment of COVID-19: a cross-sectional analysis of trials registered in ClinicalTrials.govKentaro Sakamaki, Yukari Uemura, Yosuke Shimizu
Clinical Trials (London, England)|July 17, 2023
The net benefit for time-to-event outcome in oncology clinical trials with treatment switchingMusashi Fukuda, Kentaro Sakamaki, Koji Oba
Journal of the National Cancer Institute|May 10, 2015
Detecting overall survival benefit derived from survival postprogression rather than progression-free survivalSatoshi Morita, Kentaro Sakamaki, Guosheng Yin
Clinical Trials (London, England)|January 18, 2023
Clinical trial design and analysis for comparing three treatments with intra-individual right- and left-hand dataRyunosuke Machida, Kentaro Sakamaki, Aya Kuchiba
Journal of Biopharmaceutical Statistics|January 31, 2023
Optimal dose escalation methods using deep reinforcement learning in phase I oncology trialsKentaro Matsuura, Kentaro Sakamaki, Junya Honda, et al.
Statistics in Medicine|December 15, 2025
Dynamic Prediction of Analysis Timing in Clinical Trials Using Joint Models of Longitudinal and Time-to-Event DataRyunosuke Machida, Kentaro Sakamaki, Tomohiro Ohigashi, et al.
BMJ Open|December 1, 2020
Multicentre randomised phase II study of the perioperative administration of flurbiprofen axetil in patients with non-small cell lung cancer: study protocol of the FLAX StudyKentaro Sakamaki, Katsuya Watanabe, Tetsukan Woo, et al.
Bioscience Trends|January 31, 2017
End-of-life care bonus promoting end-of-life care in nursing homes: An 11-year retrospective longitudinal prefecture-wide study in JapanSho Nishiguchi, Nagisa Sugaya, Kentaro Sakamaki, et al.
Pageof 16

Showing results (1-10 of 151) with videos related to

Sort By:
Pageof 16
Nihon Geka Gakkai Zasshi|April 16, 2016
[PRIMER FOR SURGICAL CLINICAL TRIALS]Kentaro Sakamaki, Takeharu Yamanaka
BMC Medical Research Methodology|October 3, 2022
Statistical methods and graphical displays of quality of life with survival outcomes in oncology clinical trials for supporting the estimand frameworkKentaro Sakamaki, Takuya Kawahara
Trials|November 9, 2021
Definitions and elements of endpoints in phase III randomized trials for the treatment of COVID-19: a cross-sectional analysis of trials registered in ClinicalTrials.govKentaro Sakamaki, Yukari Uemura, Yosuke Shimizu
Clinical Trials (London, England)|July 17, 2023
The net benefit for time-to-event outcome in oncology clinical trials with treatment switchingMusashi Fukuda, Kentaro Sakamaki, Koji Oba
Journal of the National Cancer Institute|May 10, 2015
Detecting overall survival benefit derived from survival postprogression rather than progression-free survivalSatoshi Morita, Kentaro Sakamaki, Guosheng Yin
Clinical Trials (London, England)|January 18, 2023
Clinical trial design and analysis for comparing three treatments with intra-individual right- and left-hand dataRyunosuke Machida, Kentaro Sakamaki, Aya Kuchiba
Journal of Biopharmaceutical Statistics|January 31, 2023
Optimal dose escalation methods using deep reinforcement learning in phase I oncology trialsKentaro Matsuura, Kentaro Sakamaki, Junya Honda, et al.
Statistics in Medicine|December 15, 2025
Dynamic Prediction of Analysis Timing in Clinical Trials Using Joint Models of Longitudinal and Time-to-Event DataRyunosuke Machida, Kentaro Sakamaki, Tomohiro Ohigashi, et al.
BMJ Open|December 1, 2020
Multicentre randomised phase II study of the perioperative administration of flurbiprofen axetil in patients with non-small cell lung cancer: study protocol of the FLAX StudyKentaro Sakamaki, Katsuya Watanabe, Tetsukan Woo, et al.
Bioscience Trends|January 31, 2017
End-of-life care bonus promoting end-of-life care in nursing homes: An 11-year retrospective longitudinal prefecture-wide study in JapanSho Nishiguchi, Nagisa Sugaya, Kentaro Sakamaki, et al.
Pageof 16